135 related articles for article (PubMed ID: 1697498)
1. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
Cooper EH; Armitage TG; Robinson MR; Newling DW; Richards BR; Smith PH; Denis L; Sylvester R
Cancer; 1990 Sep; 66(5 Suppl):1025-8. PubMed ID: 1697498
[TBL] [Abstract][Full Text] [Related]
2. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.
Smith PH; Bono A; Calais da Silva F; Debruyne F; Denis L; Robinson P; Sylvester R; Armitage TG
Cancer; 1990 Sep; 66(5 Suppl):1009-16. PubMed ID: 2144203
[TBL] [Abstract][Full Text] [Related]
3. Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.
Keuppens F; Denis L; Smith P; Carvalho AP; Newling D; Bond A; Sylvester R; De Pauw M; Vermeylen K; Ongena P
Cancer; 1990 Sep; 66(5 Suppl):1045-57. PubMed ID: 2144206
[TBL] [Abstract][Full Text] [Related]
4. Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
Denis L; Smith PH; De Moura JL; Newling DW; Bono A; Keuppens F; Robinson M; Mahler C; Sylvester R; De Pauw M
Eur Urol; 1990; 18 Suppl 3():34-40. PubMed ID: 2151274
[TBL] [Abstract][Full Text] [Related]
5. Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).
Iversen P
Eur Urol; 1990; 18 Suppl 3():41-4. PubMed ID: 2151275
[TBL] [Abstract][Full Text] [Related]
6. EORTC protocol 30853: orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatment.
Robinson MR; Denis L; Newling DW; Sylvester R; De Pauw M
Cancer; 1990 Sep; 66(5 Suppl):1022-4. PubMed ID: 2144204
[TBL] [Abstract][Full Text] [Related]
7. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
Sylvester RJ; Denis L; de Voogt H
Eur Urol; 1998; 33(2):134-43. PubMed ID: 9519354
[TBL] [Abstract][Full Text] [Related]
8. Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86.
Iversen P; Suciu S; Sylvester R; Christensen I; Denis L
Cancer; 1990 Sep; 66(5 Suppl):1067-73. PubMed ID: 2144208
[TBL] [Abstract][Full Text] [Related]
9. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.
Iversen P; Christensen MG; Friis E; Hornbøl P; Hvidt V; Iversen HG; Klarskov P; Krarup T; Lund F; Mogensen P
Cancer; 1990 Sep; 66(5 Suppl):1058-66. PubMed ID: 2144207
[TBL] [Abstract][Full Text] [Related]
10. Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).
Boccardo F; Decensi A; Guarneri D; Rubagotti A; Oneto F; Martorana G; Giuliani L; Delli Ponti U; Petracco S; Cortellini P
Eur Urol; 1990; 18 Suppl 3():48-53. PubMed ID: 2151277
[TBL] [Abstract][Full Text] [Related]
11. Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma.
Silver RI; Straus FH; Vogelzang NJ; Kellman H; Chodak GW
Urology; 1991 Jan; 37(1):17-21. PubMed ID: 1702566
[TBL] [Abstract][Full Text] [Related]
12. Value of biochemical markers in the management of disseminated prostatic cancer.
Mulders PF; Fernandez del Moral P; Theeuwes AG; Oosterhof GO; van Berkel HT; Debruyne FM
Eur Urol; 1992; 21(1):2-5. PubMed ID: 1376692
[TBL] [Abstract][Full Text] [Related]
13. Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853).
Denis L; Robinson M; Mahler C; Smith P; Keuppens F; De Moura JL; Bono A; Newling D; Sylvester R; De Pauw M
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):951-9. PubMed ID: 2149508
[TBL] [Abstract][Full Text] [Related]
14. Comparability of EORTC and DAPROCA studies in advanced prostatic cancer.
Suciu S; Sylvester R; Iversen P; Christensen I; Denis L
Cancer; 1990 Sep; 66(5 Suppl):1029-34. PubMed ID: 2144205
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
Jurincic CD; Horlbeck R; Klippel KF
Semin Oncol; 1991 Oct; 18(5 Suppl 6):21-5. PubMed ID: 1835139
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?
Leo ME; Bilhartz DL; Bergstralh EJ; Oesterling JE
J Urol; 1991 Apr; 145(4):802-6. PubMed ID: 1706440
[TBL] [Abstract][Full Text] [Related]
17. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
Dennis ER; Jia X; Mezheritskiy IS; Stephenson RD; Schoder H; Fox JJ; Heller G; Scher HI; Larson SM; Morris MJ
J Clin Oncol; 2012 Feb; 30(5):519-24. PubMed ID: 22231045
[TBL] [Abstract][Full Text] [Related]
18. The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancer.
Emtage LA; Lewis PW; Blackledge GR
Br J Urol; 1987 Dec; 60(6):572-7. PubMed ID: 2447997
[TBL] [Abstract][Full Text] [Related]
19. Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study.
Fourcade RO; Cariou G; Coloby P; Colombel P; Coulange C; Grise P; Mangin P; Soret JY; Poterre M
Eur Urol; 1990; 18 Suppl 3():45-7. PubMed ID: 2151276
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).
Collette L; de Reijke TM; Schröder FH;
Eur Urol; 2003 Aug; 44(2):182-9; discussion 189. PubMed ID: 12875936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
